# Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

> **NCT00768040** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 39 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00768040
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Inadequate enrollment
- **Last updated:** 2012-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00768040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00768040, "Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00768040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*